Rocket One (RKTO) Total Liabilities (2017 - 2026)
Rocket One's (RKTO) quarterly Total Liabilities came in at $1.4 million in Q2 2026, up 279.49% year-over-year from $364630.0 in Q2 2025, and down 3.41% quarter-over-quarter from $1.4 million in Q1 2026.
Analysis
Rocket One (RKTO) Total Liabilities (2017 - 2026) Analysis & Trends
Rocket One has disclosed Total Liabilities across 10 years of filings, most recently posting $1.4 million for Q2 2026.
- In Q2 2026, Total Liabilities rose 279.49% year-over-year to $1.4 million; the TTM figure through Jun 2026 stood at $1.4 million (up 279.49% YoY), while the FY2025 annual figure was $1.5 million, up 74.2% from the prior year.
- Total Liabilities came in at $1.4 million for Q2 2026 at Rocket One, down from $1.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $2.0 million in Q2 2023 to a low of $364630.0 in Q2 2025.
- Average Total Liabilities over 5 years is $1.1 million, with a median of $1.0 million recorded in 2022.
- Year-over-year, Total Liabilities plunged 64.81% in 2024 and soared 279.49% in 2026.
- Over 5 years, Total Liabilities stood at $1.6 million in 2022, then sank by 56.95% to $704983.0 in 2023, then rose by 18.29% to $833906.0 in 2024, then jumped by 74.2% to $1.5 million in 2025, then fell by 4.75% to $1.4 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $1.4 million in Q2 2026, $1.4 million in Q1 2026, and $1.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Rocket One | 13.86 Mn | 5.97 Mn | - | 1.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.38 Mn |
| Mar 31, 2026 | 1.43 Mn |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 364,630.00 |
| Mar 31, 2025 | 815,299.00 |
| Dec 31, 2024 | 833,906.00 |
| Sep 30, 2024 | 813,033.00 |
| Jun 30, 2024 | 691,860.00 |
| Mar 31, 2024 | 658,735.00 |
| Dec 31, 2023 | 704,983.00 |
| Sep 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | 1.97 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Sep 30, 2021 | 1.84 Mn |